2005:

December 13, 2005
Scientists Report Intermittent, Oral Dosing of the HIF-PH Inhibitor, FG-2216, Increases and Maintains Hemoglobin Levels in a Preclinical Study of Chronic Anemia

November 14, 2005
FibroGen Provides Update on the Development of FG-2216 and FG-4592, Oral Therapies for Anemia

February 16, 2005
FibroGen Completes Equity Financing

2004:

December 6, 2004
FibroGen Reports Phase 1 Results of Investigational Oral Anemia Therapy, FG-2216, and New Data from Phase 2A Study in Anemic Chronic Kidney Disease Patients

November 1, 2004
FibroGen Announces FG-3019 Improves Kidney Function in a Late-Stage Disease Model of Diabetic Nephropathy

November 1, 2004
FibroGen Investigational Small Molecule Anemia Therapy, FG-2216, Increased Endogenous EPO Production in Humans

October 27, 2004
FibroGen Announces FG-3019 Found Safe and Well Tolerated in Patients with Idiopathic Pulmonary Fibrosis

September 24, 2004
FibroGen Enters Agreement with Yamanouchi to License Erythropoietic Small Molecule in Development for the Treatment of Anemia

April 1, 2004
FibroGen Announces Three Scientific Publications Highlighting Important Medical Device and Pharmaceutical Uses of Recombinant Human Collagens and Gelatins

March 25, 2004
FibroGen Reports Advances in Targeting Hypoxia-Inducible Factor (HIF) for Drug Development

. . . to 2003 press releases